J. Krishnarajah

Most-cited papers

1. Epitope-specific immunotherapy targeting CD4+ T cells in celiac disease: evaluation in randomized, double-blind, placebo-controlled phase 1 studies

   G. Goel, T. King, A. J. Daveson, J. Andrews +24 more

   2017The Lancet Gastroenterology and Hepatology127 citations Open access

   Semantic Scholar

   Save

2. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

   Patrick F. Smith, J. Krishnarajah, P. Nunn, R. Hill +5 more

   2017British Journal of Clinical Pharmacology99 citations Open access

   Semantic Scholar

   Save

3. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults

   S. Manoff, Michele Sausser, Amy Falk Russell, Jason C. Martin +9 more

   2019Human Vaccines & Immunotherapeutics72 citations Open access

   Semantic Scholar

   Save

4. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial

   D. Kim, J. Krishnarajah, S. Lillioja, F. de Looze +6 more

   2015Diabetes, obesity and metabolism57 citations

   Semantic Scholar

   Save

5. Refined Localisation of the Genes for Nebulin and Titin on Chromosome 2q Allows the Assignment of Nebulin as a Candidate Gene for Autosomal Recessive Nemaline Myopathy

   K. Pelin, M. Ridanpää, K. Donner, S. Wilton +7 more

   1997European Journal of Human Genetics43 citations

   Semantic Scholar

   Save

6. Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?

   H. Keen, J. Krishnarajah, T. Bates, G. Watts

   2014Expert Opinion on Drug Safety38 citations

   Semantic Scholar

   Save

7. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine

   Stephen Lim, S. Schug, J. Krishnarajah

   2019Pain medicine (Malden, Mass.)11 citations

   Semantic Scholar

   Save

8. Sa1396 A Single Intradermal (ID) Injection of Nexvax2®, a Peptide Composition With Dominant Epitopes for Gluten-Reactive CD4+ T Cells, Activates T Cells and Triggers Acute Gastrointestinal Symptoms in HLA-DQ2.5+ People With Celiac Disease (CeD)

   G. Goel, Toufic Mayassi, Shuo-Wang Qiao, C. Ciszewski +20 more

   20163 citations

   Semantic Scholar

   Save

9. 846 Efficacy, Safety, Tolerability, and Immunological Effects of Nexvax2®, a Peptide-Based Therapeutic Vaccine, Administered by Intra-Dermal (ID) Injection Twice-Weekly for 8-Weeks in HLA-DQ2.5+ Celiac Disease (CeD)

   G. Goel, T. King, A. J. Daveson, J. Krishnarajah +13 more

   20162 citations

   Semantic Scholar

   Save

10. A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system.

    P. Gavin, L. Simon, T. Schlagheck, Alisha J Smith +1 more

    2017Pain Management1 citations

    Semantic Scholar

    Save

11. Sa1395 Nexvax2®, a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD)

    G. Goel, J. Andrews, R. Krause, R. Fogel +19 more

    20161 citations

    Semantic Scholar

    Save

12. Quick turnaround vital for ethical human research

    P. Leedman, J. Krishnarajah

    20140 citations

    Semantic Scholar

    Save

13. (439) A transdermal oxymorphone patch delivers therapeutic plasma concentrations of oxymorphone: an open label Phase I clinical trial

    P. Gavin, M. El-Tamimy, A. Smith, J. Krishnarajah

    20140 citations Open access

    Semantic Scholar

    Save